We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024
25 Apr 2024 - 27 Apr 2024

Breast Tumors That Display Kataegis Have a Better Prognosis

By LabMedica International staff writers
Posted on 12 Jul 2016
Print article
Image: In kataegis, multiple mutations cluster in a few hotspots in a cancer genome. Here, cytosine (C) bases are commonly substituted with thymine (T) in the DNA strand (Photo courtesy of Matteo D’Antonio, University of California, San Diego).
Image: In kataegis, multiple mutations cluster in a few hotspots in a cancer genome. Here, cytosine (C) bases are commonly substituted with thymine (T) in the DNA strand (Photo courtesy of Matteo D’Antonio, University of California, San Diego).
Breast tumors that display kataegis, a state of hypermutation that is localized to only a few genomic regions, are not highly invasiveness, and patients with cancers that possessing this marker have a good prognosis.

Kataegis is a mutational process observed in approximately 55% of breast tumors that results in hypermutation in localized genomic regions. Investigators at the University of California, San Diego (USA) used whole-genome sequence data of 97 tumors to examine the distribution of kataegis loci.

The data they obtained revealed that these somatic mutations were over-represented on chromosomes 8, 17, and 22 and depleted on chromosomes 2, 9, and 16 and were enriched in regions containing genes and functional regulatory elements. Genes in the vicinity of kataegis loci were less likely to be aberrantly expressed than genes that were located farther away. Breast cancers that contained kataegis had a transcriptome-wide expression signature that was consistent with low invasive potential and enabled the kataegis status of a tumor to be predicted using RNA sequencing (RNA-seq) data.

The investigators exploited the kataegis expression signature to predict kataegis status in 412 breast cancers with transcriptome but not whole-genome sequence data and showed that kataegis loci were enriched in high-grade, HER2+ tumors in patients diagnosed with breast cancer at an older age and who had a later age at death.

“We do not know what causes kataegis, and before this study not much was known about its functional importance at the molecular or clinical level,” said senior author Dr. Kelly Frazer, professor of pediatrics at the University of California, San Diego. “We have now found that kataegis is associated with a good prognosis for patients with breast cancer. Kataegis status might also be helpful in determining a patient’s treatment options, but there is a long way to go before kataegis status could be used in the clinic.”

The paper on kataegis in breast tumors was published in the June 30, 2016, online edition of the journal Cell Reports.

Related Links:
University of California, San Diego

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Plasma Control
Plasma Control Level 1

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.